Dr. Reddy's completed a significant block deal worth INR 182.8 crore, with each of the 1,387,520 shares trading at approximately INR 1317.2 on the National Stock Exchange (NSE).

Aditya Birla Capital has authorized a ₹4,000 crore equity issue for expansion, while Bosch India records a robust Q4 due to increased auto demand. Meanwhile, Dr. Reddy's introduces an oral semaglutide biosimilar, but Jubilant FoodWorks and Whirlpool report declining profits in their latest quarters.

Tata Motors investors are advised to hold onto their shares, setting a safety limit at Rs 350. BPCL could trade between Rs 300-320, with a support level at Rs 275, according to analysts. On the other hand, Dr. Reddy's is looking optimistic, aiming for prices between Rs 1,500-1,600, but investors should consider selling if it drops below Rs 1,250 in the June series.

Key stocks like ICICI Bank, RBL Bank, Coal India, PFC-REC, Adani Ports, HFCL, Uno Minda, and Dr Reddy's are expected to be in the spotlight due to acquisitions, approvals, and expansion plans. Highlights include Prudential's acquisition of Bharti Life stake, MCL's IPO, RBL Bank's investment in NBD, PFC-REC merger, and Adani Ports' foray into South America.

Dr. Reddy's shares climbed by 3%, reaching ₹1,343.2, following the company's Canadian launch of generic semaglutide for type-2 diabetes treatment. This rise comes on the heels of a 10% increase over the past month and builds upon their successful India launch of Obeda GLP-1 therapy.

Dr. Reddy's Labs has experienced a sharp drop in operating margins, revenue, and net profit. Urgent strategic action is required to tackle operational issues and rebuild investor trust.

Dr. Reddy's India business experienced a 20% growth in Q4 of FY26, boosted by new product launches, price increases, and higher volumes. The company has refocused its strategy on chronic therapies, innovative products, and acquisitions, which helped improve its IPM ranking to 9th.

Dr. Reddy's Q4 EBITDA experienced a significant decline of 81% year-over-year, dropping from ₹19.98B to ₹3.8B. The EBITDA margin also took a hit, shrinking dramatically from 23.4% to just 5.1% in the same period. This indicates challenging financial conditions for the company.

Dr. Reddy's Laboratories is preparing to enter the market with a generic oral semaglutide, offering an alternative diabetes treatment option in the near future.

Jefferies has downgraded Dr. Reddy's to 'Underperform', setting a price target of ₹1,040. The decision is due to weak Q4 results and pressure from underperforming in the US market. Despite growth in India, Russia, and Europe, potential hurdles like slow Semaglutide uptake in Canada and delays in Abatacept launch pose risks.

Morgan Stanley continues to rate Dr. Reddy's as equal weight, setting a price target of INR 1215, despite missing revenue and EBITDA targets due to delays in the ramp-up of Semaglutide, which is awaiting approval in Brazil. The pharmaceutical company aims to sell 6-7 million Semaglutide pens by the end of 2026, with over 40 million sales expected by fiscal year 2028.

Dr. Reddy's Labs has announced a final dividend of ₹8 per share, providing a financial benefit to its shareholders.

Today, Bharti Airtel and Cipla will announce their Q4 earnings. Notable changes include CLSA revising Dixon's target price down to Rs 10,400, while HSBC has initiated a buy recommendation for SRF at Rs 3,390. The moves by Dr Reddy's and Dixon in response to results remain to be seen.

Dr. Reddy's Q4 profits saw an 86% year-over-year decrease, reaching INR 220 crores, mainly due to profit margin erosion and increased competition for Revlimid. The company's revenue dropped by 12%, EBITDA fell by over 60%, and margins narrowed to 13%. To offset these losses, Dr. Reddy's has announced a dividend of INR 8 per share.

Nomura remains optimistic about Dr. Reddy's, predicting a price target of ₹1600, despite a dip in Q4 EBITDA. The company projects continuous high-double-digit growth, with gross margins around 50-55% and EBITDA margins near 20%, excluding Semaglutide.

The Indian market is witnessing significant selling due to negative global cues and broader economic worries. The Nifty is approaching the key support level at 23,150, having broken out of its previous consolidation range.

Dr. Reddy's has announced a dividend of INR 8 per share for the fiscal year 2026, with the Annual General Meeting scheduled on July 23, 2026. Additionally, Deloitte has been appointed as auditors, new independent directors have joined, and Mr. Sandeep Khandelwal is promoted to senior management.

Dr. Reddy's Laboratories recently executed a significant block trade on the National Stock Exchange (NSE), worth approximately INR 51.5 crore, or about $6.8 million USD. This transaction included over 400,000 shares traded at roughly INR 1261.3 per share.

Dr. Reddy's Lab anticipates SG&A costs to remain similar to FY26 levels and R&D expenses at 7-8% of revenue for FY27. The North American division is expected to experience a significant growth, primarily due to increased Semaglutide sales in the region.

Dr. Reddy's anticipates Semaglutide will sell between $25 and $30 per unit, with higher prices in certain markets. The company forecasts biosimilar sales of $0.5 billion to $0.7 billion by the fiscal year 2029, while capital expenditure for the current fiscal year stands at INR 2,000 crores (approximately $263 million).

Over 470 companies, including pharmaceutical firms like Dr. Reddy's and Cipla, steel manufacturers such as Tata Steel and SAIL, along with Airtel, are set to release their Q4 results. The attention is now on the performance of the pharma sector, PSUs (Public Sector Undertakings), and large-cap companies. Several of these might propose dividends this week, signaling positive financial health.

Analysts from various brokerages are optimistic about the future of Sun Pharma, Dr Reddy's, Granules India, and Mankind Pharma, anticipating a potential increase of up to 21% in their share prices.

Dr. Reddy's has received Health Canada's approval for a generic semaglutide injection, marking them as the first company authorized to distribute it in Canada. This move positions Dr. Reddy's as the initial market entrant for this product.

The Delhi High Court has instructed Dr. Reddy's to rebrand its weight-loss drug, currently known as "Olymviq." Starting from March 30th, the new brand name will be "Olymra" due to a trademark issue. Compliance details are requested by the court.

Dr. Reddy's could see intensified competition in Canada's market for semaglutide, potentially leading to changes in market dynamics with increased competitors and potential price increases.

Dr. Reddy's receives Canadian approval for a generic version of Ozempic, which could potentially reduce the medication's monthly cost due to increased competition.

The Nifty Pharma index experienced a 3% rise today, with notable gains from Piramal Pharma (up 9%) and Dr Reddy's Laboratories (up 8%). This increase is attributed to the success of Obeda launch by Dr Reddy's in the GLP-1 market and new API contracts secured by Piramal Pharma.

Dr. Reddy's has received approval to introduce a generic version of oral semaglutide, enabling them to produce and distribute three different formulations of the drug.

Bank of America increased Dr. Reddy's Laboratories price target to ₹1,540, driven by semaglutide catalyst and robust earnings diversification. The company's margin resilience is expected to withstand geopolitical risks and revenue delays, maintaining margins above 20%.

Sun Pharma and Cipla are anticipated to see a 12% increase in Q4 revenue for FY26, according to Systematix. However, earnings are projected to drop by 14%. Lupin is expected to show a significant 60% YoY growth in earnings, while Dr. Reddy's could experience steep declines due to gRevlimid no longer being a factor.

Citi maintains a 'Sell' rating on Dr. Reddy's, lowering its target price to ₹1,070 due to a rejection of its Semaglutide generic by Brazilian health authority ANVISA. Meanwhile, Apotex's tentative US approval could potentially give it an edge in the Canadian market over Dr. Reddy's.

Dr. Reddy's Labs has offloaded its subsidiary Svaas Wellness for INR 2.23 crore to Enspirit Tech, a company not related to the pharmaceutical giant. This sale accounted for less than 1% of their total revenue in the fiscal year 2025.

Pharmaceutical companies like Dr. Reddy's and Lupin in India are integrating Artificial Intelligence (AI) into their operations for drug discovery, trials, and manufacturing. A discussion on AI's influence within the pharmaceutical sector was held with experts from PwC India, Dr. Reddy's, and Lupin by The Economic Times.